Anakinra (Raleukin) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Anakinra is the first biological agent to block the pro-inflammatory effects^[1][2]. IC50 & Target: IL-1R^[1]. In Vivo: Combined etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, I.P. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice^[2].
Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan^[3].